Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 0.00% is 100% above its 5-year average of -1668.49%, near the high end of its 5-year range (-17054.43%–0.00%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
-1668.49%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Gain Therapeutics, Inc.
Market Cap
$71.23M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-1668.49%
Market Cap
$70.63M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$72.32M
Net Profit Margin
-102.84%
TTM Avg
-531.21%
3Y Avg
-660.25%
5Y Avg
-488.89%
Market Cap
$72.83M
Net Profit Margin
-105.29%
TTM Avg
-106.48%
3Y Avg
-112.00%
5Y Avg
-95.88%
Market Cap
$69.61M
Net Profit Margin
-1.87%
TTM Avg
3.14%
3Y Avg
-4.53%
5Y Avg
-2.69%
Market Cap
$73.27M
Net Profit Margin
-210.75%
TTM Avg
-289.10%
3Y Avg
-513.23%
5Y Avg
-2388.54%
Market Cap
$68.90M
Net Profit Margin
17.18%
TTM Avg
-64.27%
3Y Avg
-50.52%
5Y Avg
-660.79%
Market Cap
$68.10M
Net Profit Margin
163.32%
TTM Avg
-34.49%
3Y Avg
-63.76%
5Y Avg
-75.19%
Market Cap
$67.52M
Net Profit Margin
-33044.00%
TTM Avg
-18819.13%
3Y Avg
-12177.01%
5Y Avg
-8726.92%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $71.23M | 0.00% | 0.00% | 0.00% | -1668.49% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $70.63M | 0.00% | 0.00% | 0.00% | 0.00% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | -102.84% | -531.21% | -660.25% | -488.89% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | -105.29% | -106.48% | -112.00% | -95.88% |
| Champions Oncology, Inc. (CSBR)vs › | $69.61M | -1.87% | 3.14% | -4.53% | -2.69% |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | -210.75% | -289.10% | -513.23% | -2388.54% |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 17.18% | -64.27% | -50.52% | -660.79% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | 163.32% | -34.49% | -63.76% | -75.19% |
| iBio, Inc. (IBIO)vs › | $67.52M | -33044.00% | -18819.13% | -12177.01% | -8726.92% |
| Pulmonx Corporation (LUNG)vs › | $75.18M | -55.03% | -63.48% | -81.34% | -87.39% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | -9310.11% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | -5347.33% |
| 2022-03-31 | -7271.57% |
| 2021-12-31 | -7452.17% |
| 2021-09-30 | -17054.43% |
| 2021-06-30 | -3988.53% |
| 2021-03-31 | -46506.87% |
| 2020-12-31 | -18116.65% |
| 2020-09-30 | -11863.37% |
| 2020-06-30 | -8526.00% |
| 2020-03-31 | -8755.70% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | -5311.00% |
| 2019-06-30 | -5311.00% |
| 2019-03-31 | -5311.00% |
| 2018-09-30 | -5364.62% |
| 2018-06-30 | -5364.62% |
| 2018-03-31 | -5364.62% |
